|
Category:natural substances and extractives
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 93.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 583.00 to 584.00 °C. @ 760.00 mm Hg (est)
|
| Flash Point: | 610.00 °F. TCC ( 321.00 °C. ) (est)
|
| logP (o/w): | 6.548 (est) |
| Soluble in: |
| | water, 0.002016 mg/L @ 25 °C (est) |
| Insoluble in: |
| | water |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
oral-rat LD50 100 mg/kg
LUNGS, THORAX, OR RESPIRATION: CYANOSIS
BEHAVIORAL: ATAXIA
Arzneimittel-Forschung. Drug Research. Vol. 17, Pg. 79, 1967.
oral-rabbit LDLo 1000 mg/kg
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 82, Pg. 1, 1950.
oral-mouse LD50 525 mg/kg
BEHAVIORAL: EXCITEMENT
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Arzneimittel-Forschung. Drug Research. Vol. 17, Pg. 79, 1967.
oral-guinea pig LD50 130 mg/kg
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 8, Pg. 281, 1949.
intramuscular-mouse LD50 600 mg/kg
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 8, Pg. 281, 1949.
intramuscular-rat LD50 330 mg/kg
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 8, Pg. 281, 1949.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 600 mg/kg
"CRC Handbook of Antibiotic Compounds," Vols.1- , Berdy, J., Boca Raton, FL, CRC Press, 1980Vol. 8(2), Pg. 39, 1982.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | | natural substances and extractives |
| Recommendation for lupulon usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for lupulon flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
| EPI System: View |
| AIDS Citations:Search |
| Cancer Citations:Search |
| Toxicology Citations:Search |
| EPA ACToR:Toxicology Data |
| EPA Substance Registry Services (SRS):Registry |
| Laboratory Chemical Safety Summary :68051 |
| National Institute of Allergy and Infectious Diseases:Data |
| 3,5-dihydroxy-2-(3-methylbutanoyl)-4,6,6-tris(3-methylbut-2-enyl)cyclohexa-2,4-dien-1-one |
| Chemidplus:0000468280 |
References:
| | 3,5-dihydroxy-2-(3-methylbutanoyl)-4,6,6-tris(3-methylbut-2-enyl)cyclohexa-2,4-dien-1-one |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 68051 |
| Pubchem (sid): | 135025678 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| b- | bitter acid | | beta- | bitter acid | | 2,4- | cyclohexadien-1-one, 3,5-dihydroxy-2,6,6-tris(3-methyl-2-butenyl)-4-(3-methyl-1-oxobutyl)- | | 2,4- | cyclohexadien-1-one, 3,5-dihydroxy-4-isovaleryl-2,6,6-tris(3-methyl-2-butenyl)- | | 3,5- | dihydroxy-2-(3-methylbutanoyl)-4,6,6-tris(3-methylbut-2-en-1-yl)cyclohexa-2,4-dien-1-one | | 3,5- | dihydroxy-2-(3-methylbutanoyl)-4,6,6-tris(3-methylbut-2-enyl)cyclohexa-2,4-dien-1-one | | 3,5- | dihydroxy-2,6,6-tris(3-methyl-2-butenyl)-4-(3-methyl-1-oxobutyl)-2,4-cyclohexadien-1-one | | b- | lupulic acid | | | lupulone |
Articles:
| PubMed:Antituberculous activity and toxicity of lupulon for the mouse. |
| PubMed:Lupulon, an antibiotic extracted from the strobiles of Humulus lupulus. |
| PubMed:EFFECT OF ANTIBIOTIC DRUGS ON ANTISTAPHYLOCOCCAL ACTIVITY OF LUPULON AND HEXAHYDROLUPULON. |
| PubMed:Tolerance and effects of lupulon in man. |
| PubMed:FACTORS INFLUENCING THE ANTIBIOTIC ACTIVITY OF LUPULON. |
| PubMed:Protection of Lupulon and Humulon by Ascorbic Acid. |
| PubMed:Antifungal activity of hop resin constituents and a new method for isolation of lupulon. |
| PubMed:[Lupulon and humulon, their antibacterial effects and therapeutic use in tuberculous infections]. |
| PubMed:[Effect of lupulon in experimental tuberculosis of mice]. |
| PubMed:Lupulon and humulon, antibiotic constituents of hops. |
| PubMed:LUPULON AND HUMULON-ANTIBIOTIC CONSTITUENTS OF HOPS. |
| PubMed:An investigation into the anticancer effects and mechanism of action of hop β-acid lupulone and its natural and synthetic derivatives in prostate cancer cells. |
| PubMed:The effects of beta acids from hops (Humulus lupulus) on mortality of Varroa destructor (Acari: Varroidae). |
| PubMed:On the reaction of lupulones, hops β-acids, with 1-hydroxyethyl radical. |
| PubMed:Hop bitter acids inhibit tumorigenicity of hepatocellular carcinoma cells in vitro. |
| PubMed:HlPT-1, a membrane-bound prenyltransferase responsible for the biosynthesis of bitter acids in hops. |
| PubMed:Chicken intestine microbiota following the administration of lupulone, a hop-based antimicrobial. |
| PubMed:Application of plant-based antimicrobials for the growth inhibition of clostridia in pressed beet pulp silage. |
| PubMed:Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells. |
| PubMed:Early modulation of gene expression used as a biomarker for chemoprevention in a preclinical model of colon carcinogenesis. |
| PubMed:In vitro evaluation of antibacterial, anticollagenase, and antioxidant activities of hop components (Humulus lupulus) addressing acne vulgaris. |
| PubMed:Capillary zone electrophoresis method for determination of bitter (alpha- and beta-) acids in hop (Humulus lupulus L.) cone extracts. |
| PubMed:Antilisterial activity of hops beta acids in broth with or without other antimicrobials. |
| PubMed:Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAIL-receptors, in human colon tumor cells and in their derived metastatic cells. |
| PubMed:Antimicrobial activity of lupulone against Clostridium perfringens in the chicken intestinal tract jejunum and caecum. |
| PubMed:Positive antibacterial co-action between hop (Humulus lupulus) constituents and selected antibiotics. |
| PubMed:Antiangiogenic properties of lupulone, a bitter acid of hop cones. |
| PubMed:Antioxidative activity of hop bitter acids and their analogues. |
| PubMed:[Detection of sedative-hypnotic active ingredients in hops. 5. Degradation of bitter acids to 2-methyl-3-buten-2-ol, a hop constituent with sedative-hypnotic activity]. |
| PubMed:Antagonistic effect of serum on bacteriostatic action of lupulone. |
| PubMed:Chemopreventive effects of lupulone, a hop {beta}-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. |
| PubMed:Prenylflavonoids and phloroglucinol derivatives from hops (Humulus lupulus). |
| PubMed:Formation and accumulation of alpha-acids, beta-acids, desmethylxanthohumol, and xanthohumol during flowering of hops (Humulus lupulus L.). |
|
3D/inchi